Dose Evaluation of Head and Neck Cancer IMRT Treatment Planning Based on Gamma Index Analysis of Varian Halcyon 2.0 Linac

Varian Halcyon 2.0 linear accelerator was launched and became available for clinical use in 2018. Therefore, it is necessary to evaluate the accuracy of exit fluence of the Halcyon 2.0 for quality assurance (QA) of head and neck cancer treatment planning, pretreatment, and treatment. The accuracy of...

Full description

Bibliographic Details
Main Authors: W. Purwati, F. Suhaimi, W. E. Wibowo, S. A. Pawiro
Format: Article
Language:English
Published: Center for Development of Nuclear Informatics, National Nuclear Energy Agency (BATAN) 2023-03-01
Series:Atom Indonesia
Subjects:
Online Access:https://aij.batan.go.id/index.php/aij/article/view/1203
_version_ 1797730982866976768
author W. Purwati
F. Suhaimi
W. E. Wibowo
S. A. Pawiro
author_facet W. Purwati
F. Suhaimi
W. E. Wibowo
S. A. Pawiro
author_sort W. Purwati
collection DOAJ
description Varian Halcyon 2.0 linear accelerator was launched and became available for clinical use in 2018. Therefore, it is necessary to evaluate the accuracy of exit fluence of the Halcyon 2.0 for quality assurance (QA) of head and neck cancer treatment planning, pretreatment, and treatment. The accuracy of the exit fluence for twenty treatment plannings has been evaluated by conducting gamma analysis for QA pretreatment and treatment in each field and composite field by using criteria for gamma index 3 %/3 mm and 2 %/2 mm. The QA pretreatment results are in the average value for each criterion for each field and composite fields on actual gantry angle and null gantry angle with gamma passing rate (GPR) of over 99 % (range 99.78 %-99.95 %) The total treatments consisted of 2717 fractions. The analysis results of GPR for fields were 99.32 % and 97.74 % for gamma indexes of 3 %/3 mm and 2 %/2 mm, respectively. In addition, the analysis results of GPR for composites were 95.46 % and 81.38 % for gamma indexes of 3 %/3 mm and 2 %/2 mm, respectively. Based on this result, the average GPRs of QA pretreatment are ≈ 99 % of the total pixels. This means the prediction dose of Varian Halcyon 2.0 is accurate. The average GPRs of treatment is nearly  90 %, showing that Varian Halcyon 2.0 is effective for creating treatment plans for complex cases.
first_indexed 2024-03-12T11:52:00Z
format Article
id doaj.art-e4c0e786c2d041d9a992810dc3c419f0
institution Directory Open Access Journal
issn 0126-1568
language English
last_indexed 2024-03-12T11:52:00Z
publishDate 2023-03-01
publisher Center for Development of Nuclear Informatics, National Nuclear Energy Agency (BATAN)
record_format Article
series Atom Indonesia
spelling doaj.art-e4c0e786c2d041d9a992810dc3c419f02023-08-31T06:50:09ZengCenter for Development of Nuclear Informatics, National Nuclear Energy Agency (BATAN)Atom Indonesia0126-15682023-03-0111273210.55981/aij.2023.1203511Dose Evaluation of Head and Neck Cancer IMRT Treatment Planning Based on Gamma Index Analysis of Varian Halcyon 2.0 LinacW. Purwati0F. Suhaimi1W. E. Wibowo2S. A. Pawiro3Department of Physics, Faculty of Mathematics and Natural Sciences, Universitas IndonesiaDepartment of Radiation Oncology, Cipto Mangunkusumo General HospitalDepartment of Radiation Oncology, Cipto Mangunkusumo General HospitalDepartment of Physics, Faculty of Mathematics and Natural Sciences, Universitas IndonesiaVarian Halcyon 2.0 linear accelerator was launched and became available for clinical use in 2018. Therefore, it is necessary to evaluate the accuracy of exit fluence of the Halcyon 2.0 for quality assurance (QA) of head and neck cancer treatment planning, pretreatment, and treatment. The accuracy of the exit fluence for twenty treatment plannings has been evaluated by conducting gamma analysis for QA pretreatment and treatment in each field and composite field by using criteria for gamma index 3 %/3 mm and 2 %/2 mm. The QA pretreatment results are in the average value for each criterion for each field and composite fields on actual gantry angle and null gantry angle with gamma passing rate (GPR) of over 99 % (range 99.78 %-99.95 %) The total treatments consisted of 2717 fractions. The analysis results of GPR for fields were 99.32 % and 97.74 % for gamma indexes of 3 %/3 mm and 2 %/2 mm, respectively. In addition, the analysis results of GPR for composites were 95.46 % and 81.38 % for gamma indexes of 3 %/3 mm and 2 %/2 mm, respectively. Based on this result, the average GPRs of QA pretreatment are ≈ 99 % of the total pixels. This means the prediction dose of Varian Halcyon 2.0 is accurate. The average GPRs of treatment is nearly  90 %, showing that Varian Halcyon 2.0 is effective for creating treatment plans for complex cases.https://aij.batan.go.id/index.php/aij/article/view/1203halcyon 2.0head and neck cancergamma index analysisepid-portal dosimetry
spellingShingle W. Purwati
F. Suhaimi
W. E. Wibowo
S. A. Pawiro
Dose Evaluation of Head and Neck Cancer IMRT Treatment Planning Based on Gamma Index Analysis of Varian Halcyon 2.0 Linac
Atom Indonesia
halcyon 2.0
head and neck cancer
gamma index analysis
epid-portal dosimetry
title Dose Evaluation of Head and Neck Cancer IMRT Treatment Planning Based on Gamma Index Analysis of Varian Halcyon 2.0 Linac
title_full Dose Evaluation of Head and Neck Cancer IMRT Treatment Planning Based on Gamma Index Analysis of Varian Halcyon 2.0 Linac
title_fullStr Dose Evaluation of Head and Neck Cancer IMRT Treatment Planning Based on Gamma Index Analysis of Varian Halcyon 2.0 Linac
title_full_unstemmed Dose Evaluation of Head and Neck Cancer IMRT Treatment Planning Based on Gamma Index Analysis of Varian Halcyon 2.0 Linac
title_short Dose Evaluation of Head and Neck Cancer IMRT Treatment Planning Based on Gamma Index Analysis of Varian Halcyon 2.0 Linac
title_sort dose evaluation of head and neck cancer imrt treatment planning based on gamma index analysis of varian halcyon 2 0 linac
topic halcyon 2.0
head and neck cancer
gamma index analysis
epid-portal dosimetry
url https://aij.batan.go.id/index.php/aij/article/view/1203
work_keys_str_mv AT wpurwati doseevaluationofheadandneckcancerimrttreatmentplanningbasedongammaindexanalysisofvarianhalcyon20linac
AT fsuhaimi doseevaluationofheadandneckcancerimrttreatmentplanningbasedongammaindexanalysisofvarianhalcyon20linac
AT wewibowo doseevaluationofheadandneckcancerimrttreatmentplanningbasedongammaindexanalysisofvarianhalcyon20linac
AT sapawiro doseevaluationofheadandneckcancerimrttreatmentplanningbasedongammaindexanalysisofvarianhalcyon20linac